Evaluation of donepezil and rivastigmine administration on the cognitive deficits induced by electroconvulsive therapy: a randomized, double-blind clinical trial

• Authors: Nazarinasab Masoumeh , Behrouzian Forouzan , Mahnoo Mahnoosh

Abstracts

Background. Although several medical interventions have been used to reduce the cognitive side effects of electroconvulsive therapy (ECT), no specific drug has been yet identified to solve this problem. Objectives. Because donepezil and rivastigmine are used to reduce the cognitive deficits in Alzheimer’s patients, this study evaluated the effectiveness of these drugs on cognitive function in patients treated with ECT. Material and methods. This randomized, double-blind clinical trial was performed on 60 patients with various mental disorders who were undergoing ECT as non-hospitalized patients or in the psychiatric ward of Golestan Hospital in Ahvaz, Iran. The subjects were divided into 3 groups of patients, receiving either donepezil, rivastigmine or a placebo. The Mini-Mental State Examination scores (MMSE) of the patients were evaluated before the initial ECT session, after the middle ECT session and after the final ECT session; the collected data were then analyzed using SPSS software version 22. Results. The patients consisted of 25 females and 35 males at a mean age of 32.65 ± 8.81 years. The mean total number of ECT sessions was 7.41 ± 1.86 (p = 0.357). The mean of MMSE scores before the initial ECT session was 26.41 ± 1.35 in all patients, without a significant difference between the groups (p = 0.387). The mean of MMSE scores after the middle ECT session was 26.70 ± 1.41 for the donepezil group, 26.25 ± 1.29 for the rivastigmine group and 24.75 ± 2.07 for the placebo group; the MMSE scores of the placebo group were significantly lower (p = 0.003). Also, the mean of MMSE scores after the final ECT session was 26.75 ± 1.29 for the donepezil group, 26.40 ± 1.31 for the rivastigmine group and 24.50 ± 1.84 for the placebo group, which shows significantly lower scores in the placebo group (p < 0.001). The correlation between age and MMSE score after the ECT sessions was negatively correlated in the donepezil group. Conclusions. The mean of MMSE scores in the placebo group was significantly lower than the donepezil and rivastigmine groups in the middle of the ECT and after the final ECT sessions.

Keywords

electroconvulsive therapy; donepezil; rivastigmine

• Publisher: Stowarzyszenie Przyjaciół Medycyny Rodzinnej i Lekarzy Rodzinnych
• Journal: Family Medicine & Primary Care Review
• Year: 2019
• Issue: 3
• Pages: 243-248

Contributors

author

Nazarinasab Masoumeh

author

Behrouzian Forouzan

author

Mahnoo Mahnoosh

References

• Nazarinasab M, Motamedfar A, Nematpour S, et al. Assessment of depression after stroke and its relation to brain lesion. Minerva Psichiatrica 2018; 59(1): 39–44.
• Nazarinasab M, Motamedfar A, Moqadam AE. Investigating mental health in patients with osteoarthritis and its relationship with some clinical and demographic factors. Reumatologia 2017; 55(4): 183–188
• Nazarinasab M, Motamedfar A, Najafian M, et al. Investigating the effects of relaxation therapy on decreasing anxiety in patients with elective caesarean section in Imam Khomeini Hospital, Ahvaz, Iran during 2016. Stud Med 2018; 34(2): 107–111.
• Nazarinasab M, Behrouzian F, Salmanpour R. Evaluating the effectiveness of zinc sulfate in improving depression symptoms in patients treated with selective serotonin reuptake inhibitors in Golestan Hospital in Ahvaz, Iran. Minerva Psichiatrica 2017; 58(3): 156–161.
• Sengul MCB, Kenar ANI, Hanci E, et al. Practice of acute and maintenance electroconvulsive therapy in the Psychiatric Clinic of a University Hospital from Turkey: between 2007 and 2013. Clin Psychopharmacol Neurosci 2016; 14(1): 57–63.
• Szepietowska E, Kuzaka A. Depressed mood and cognitive deficits as distinct mechanisms of subjective memory and executive complaints.Current Issues in Personality Psychology 2019; 7(1): 43–52, doi: 10.5114/cipp.2018.81689.
• Napierała M, Pucher B, Polski B, et al. Perception of speech in mood disorders. Neuropsychiatria i Neuropsychologia/Neuropsychiatry and Neuropsychology 2018; 13(2): 75–82, doi: 10.5114/nan.2018.79609
• Vanelle JM, Sauvaget-Oiry A, Juan F. Indications for electroconvulsive therapy. Presse Med 2008; 37(5 Pt 2): 889–893.
• Rasmussen KG. Electroconvulsive therapy and melancholia: review of the literature and suggestions for further study. J ECT 2011; 27:315–322.
• Weiner RD. Retrograde amnesia with electroconvulsive therapy: characteristics and implications. Arch Gen Psychiatry 2000; 57: 591–592.
• Joun PR. Electroconvulsive therapy. In: Sadock BJ, Sadock VA, Ruiz P, eds. Comprehensive textbook of psychiatry. 9th ed. New York: Lippincott Williams & Wilkins; 2009: 3285–3314.
• Sienaert P. What we have learned about electroconvulsive therapy and its relevance for the practicing psychiatrist. Can J Psychiatry 2011; 56(1): 5–12.
• Sadock B, Sadock V. Synopsis of psychiatry. 10th ed. Philadelphia: Lippincot Williams and Wilkins; 2014: 1065–1072.
• Mohagheghi A, Arfaie A, Amiri S, et al. Preventive effect of liothyronine on electroconvulsive therapy-induced memory deficit in patients with major depressive disorder: a double-blind controlled clinical trial. Biomed Res Int 2015; 503918, doi: 10.1155/2015/503918.
• Takeda A, Loveman E, Clegg A, et al. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer’s disease. Int J Geriatr Psychiatry 2006; 21(1): 17–28.
• Zink M, Sartorius A, Lederbogen F, et al. Electroconvulsive therapy in a patient receiving rivastigmine. J ECT 2002; 18(3): 162–164.
• Matthews JD, Siefert CJ, Blais MA, et al. A double-blind, placebo-controlled study of the impact of galantamine on anterograde memory impairment during electroconvulsive therapy. J ECT 2013; 29(3): 170–178, doi: 10.1097/YCT.0b013e31828b3523.
• Campos C, Rocha NB, Vieira RT, et al. Treatment of cognitive deficits in Alzheimer’s disease: a psychopharmacological review. Psychiatr Danub 2016; 28(1): 2–12
• Kirov GG, Owen L, Ballard H, et al. Evaluation of cumulative cognitive deficits from electroconvulsive therapy. Br J Psychiatr 2016;208(3): 266–270.
• American Psychiatric Association. The practice of electroconvulsive therapy – recommendations for treatment, training, and privileging (A Task Force Report of the American Psychiatric Association). 2nd ed. Washington: American Psychiatric Press; 2001.
• 21. Letter B. Studies on the role of brain cholinergic system in the therapeutic mechanisms and adverse effect on ect and lithium. Biol Psychiatry 1985; 20: 20–40.
• Lerer B, Stanley M, McIntyre I, et al. Electroconvulsive shock and brain muscarinic receptors: relationship to anterograde amnesia. Life Sci 1984; 35: 2659–2664.
• Martin DM, Katalinic N, Ingram A, et al. A new early cognitive screening measure to detect cognitive side-effects of electroconvulsive therapy? J Psychiatr Res 2013; 47(12): 1967–1974
• 24. Prakash J, Kotwal A, Prabhu H. Therapeutic and prophylactic utility of the memory-enhancing drug donepezil hydrochloride on cognition of patients undergoing electroconvulsive therapy: a randomized con-trolled trial. J ECT 2006; 22(3): 163–16
• Stryjer R, Ophir D, Bar F, et al. Rivastigmine treatment for the prevention of electroconvulsive therapy induced memory deficits in patients with schizophrenia. Clin Neuropharmacol 2012; 35: 161–164, doi: 10.1097/WNF.0b013e31825e7945